Who are ALKS 2680 Dose 1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ACP-204.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alks-2680-dose-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ALKS 2680 Dose 1 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ALKS 2680 Dose 1 (ALKS 2680 Dose 1) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscarinic M1 receptor partial agonist. Area: Psychiatry/Neurology.

phase 3 Muscarinic M1 receptor partial agonist M1 muscarinic acetylcholine receptor Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ALKS 2680 Dose 1 (ALKS 2680 Dose 1) — Alkermes, Inc.. ALKS 2680 is a muscarinic M1 receptor partial agonist designed to enhance cognitive function and treat psychiatric symptoms.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ALKS 2680 Dose 1 TARGET	ALKS 2680 Dose 1	Alkermes, Inc.	phase 3	Muscarinic M1 receptor partial agonist	M1 muscarinic acetylcholine receptor
ACP-204	ACP-204	ACADIA Pharmaceuticals Inc.	phase 3	Muscarinic M1 receptor agonist	M1 muscarinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscarinic M1 receptor partial agonist class)

Alkermes, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALKS 2680 Dose 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/alks-2680-dose-1. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing